Mepolizumab
Q&A: Mepolizumab marks second biologic approved for COPD with eosinophilic phenotype
The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, marking the second biologic approved as an add-on maintenance treatment in this patient population.
Disease burden in eosinophilic granulomatosis polyangiitis improves with mepolizumab
Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes with mepolizumab at 12 months, according to a study published in Annals of Allergy, Asthma & Immunology.
Hyperpolarized gas helps quantify ventilation defect percentages in patients with asthma
SAN FRANCISCO — Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a poster presented at the American Thoracic Society International Conference.
FDA approves mepolizumab for COPD with eosinophilic phenotype
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press release.
Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks
SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 weeks, according to study findings.
Low persistence in biologic therapy linked to asthma exacerbations, steroid use
SAN FRANCISCO — Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, according to an abstract presented at the American Thoracic Society International Conference.
Mepolizumab reduces exacerbations in COPD with type 2 inflammation
With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England Journal of Medicine.
Dupilumab, tezepelumab lead biologic initiations for severe asthma
SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.
Mepolizumab lowers repeat surgery risk for CRSwNP regardless of number of past surgeries
SAN DIEGO — Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not alter the benefits of mepolizumab on nasal polyp and VAS scores, according to a presentation here.
Risk factors impact denials, wait times, discontinuations in biologic treatment for asthma
SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.